MannKind Corp. has entered an agreement to purchase Pfizer’s insulin facility in Frankfurt, Germany and assets related to the production of bulk insulin for $33 million, subject to certain adjustments. This includes the relevant property rights, production equipment, a quantity of bulk insulin and a license to manufacture bulk insulin for use in pulmonary delivery. At MannKind’s option, as much as $30 million worth of the company’s common stock may be issued to Pfizer at closin...